Drug Approval | March 17, 2022
USFDA approves Rinvoq for ulcerative colitis
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
The centre will initially employ 170 engineers, bringing the total number of Boston Scientific’s R&D employees in India to more than 300
The TAT-5000 and the TAT-2000 thermometers for professional use by doctors and nurses and the TAT-2000C thermometer for consumer applications are based on a very innovative infrared technology
A growing portfolio of chemicals is part of a larger quality management system that sets new standards in bioprocessing
The initial SARS-CoV-2 research program at Calibr, the drug discovery and development division of Scripps Research, was supported by funding from the Bill & Melinda Gates Foundation
The award recognizes and supports promising women scientists
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Tislelizumab is now approved for seven indications in China
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Subscribe To Our Newsletter & Stay Updated
